# A Study of RC148 As a Single Agent and Combination Therapy in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors

Source: https://onco.cc/trials/nct06016062/  
OnCo record `nct06016062` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Docetaxel and Bevacizumab in advanced solid tumours, run by RemeGen Co., Ltd., now recruiting.

## Summary

A Study of RC148 As a Single Agent and Combination Therapy in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors is a phase 1/2 interventional study registered as NCT06016062 by RemeGen Co., Ltd., with 221 participants planned, started 2023-09-14 and due to reach its primary completion in 2025-12-31. Interventions recorded: RC148 Monotherapy, RC148+docetaxel Combination Therapy, RC148+RC48 Combination Therapy, RC148+RC88 Combination Therapy and RC148/Bevacizumab+RC88 Combination Therapy.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06016062
- Phase: 1/2
- Setting: A Multi-center Phase I/II Trial to Evaluate the Efficacy and Safety of RC148 As a Single Agent and Combination Therapy in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors
- Sponsor: RemeGen Co., Ltd.
- Enrolled: 221

## Sources

- ClinicalTrials.gov NCT06016062: https://clinicaltrials.gov/study/NCT06016062

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Docetaxel](https://onco.cc/drugs/docetaxel/)
- companies: [RemeGen](https://onco.cc/companies/remegen/)

---
JSON: https://onco.cc/api/v1/entities/nct06016062.json